SOLO-1 Phase III trial demonstrates Lynparza maintenance therapy cut risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer
60% of patients receiving Lynparza remained progression-free at three years compared to 27% on placebo following platinum-based chemotherapy
Lynparza is the only PARP inhibitor to demonstrate an improvement in progression-free survival as 1st-line maintenance treatment for advanced ovarian cancer
https://www.investegate.co.uk/astrazene ... 00066889E/